secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2025-11-25T23:59:59+00:00
Accession:  0001193125-25-294454
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

Personalis gets CMS revised reimbursement rates for NeXT Personal breast cancer test
--------------------------------------------------------------------------------

- CMS revised reimbursement for Personalis' NeXT Personal Dx Breast MRD test to $4,266 effective Dec 1, 2025
- Reimbursement for NeXT Personal Single Plasma Test set at $1,164, available up to six years post-treatment
- Medicare coverage for the NeXT Personal Dx test is available once per cancer diagnosis for stage II/III breast cancer

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525294454/0001193125-25-294454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525294454/d937100d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-294454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer